Propofol Injection, Emulsion
Product Images NDC 51662-1470

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Propofol (NDC 51662-1470). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adverse 1 (Adverse Reactions 1)

This appears to be a report on the side effects of anesthesia and MAC Sedation. It includes information on possible cardiovascular side effects, such as bradycardia and tachycardia, as well as hypotension and hypertension. There may be associated movement issues and burning or stinging pain at the injection site. Other possible side effects may include metabolic/nutritional changes, respiratory issues, and skin-related symptoms such as rash or pruritus.*

FDA Label Image

Adverse 2 (Adverse Reactions 2)

FDA Label Image

Adverse 3 (Adverse Reactions 3)

FDA Label Image

Clinical P Image (Clinical P Image)

This appears to be a chart or graph related to the target plasma propofol concentration and recovery time after different durations of infusion. However, without more context or a clearer image, it is difficult to provide a more specific description.*

FDA Label Image

Clinical P Tables (Clinical P Tables)

The text is a table showing the pediatric induction and maintenance doses of anesthesia for different age ranges. The table includes the median and range of induction dose and injection duration, as well as the maintenance dosage and duration for each age range.*

FDA Label Image

Dosage 1 (Dosage 1)

This document appears to be describing medication dosing guidelines for anesthesia during surgery using a combination of opioids and propofol injectable emulsion. The guidelines provide details on the recommended dosages for preinduction, anxiolysis, induction, and maintenance stages based on the patient's weight and clinical response.*

FDA Label Image

Dosage 2 (Dosage 2)

FDA Label Image

How Supplied (How Supplied)

This is a product description for a pharmaceutical product that comes in three different concentrations: 200 mg/20 mL, 500 mg/50 mL, and 1000 mg/100 mL. The product is sold in cartons of 5 flip-top vials for the 200 mg/20 mL concentration and trays of 20 flip-top vials for the 500 mg/50 mL concentration and trays of 10 flip-top vials for the 1000 mg/100 mL concentration. The concentration of the product is 10 mg/mL for all variations.*

FDA Label Image

Indications & Usage (Indications And Usage)

This text provides information about the indications and approved patient populations for Monitored Anesthesia Care sedation, combined sedation and regional anesthesia, induction and maintenance of general anesthesia, and ICU sedation. It specifies that the use of MAQ sedation is approved for adults only, while combined sedation and regional anesthesia is also approved for adults but with precautions. It also outlines age limits for the induction and maintenance of general anesthesia. Finally, it states that ICU sedation is approved for intubated, mechanically ventilated adult patients only.*

FDA Label Image

Logo (Logo)

FDA Label Image

Serialized Vial Labeling (Serialized Labeling Resized)

FDA Label Image

Structure (Structure)

FDA Label Image

Vial Option 1 (Vial Label Option 1)

This is a description of a medication called "lumzfllus BENTILALCOHOL" administered by intravenous infusion. The label advises shaking the bottle before use and using aseptic technique during administration. The dosages are listed as 100 mg, 25 mg, 10-15 g, or 0.7 g and further instructions are available on the USP guidelines. Temperature is also a concern which should be monitored during storage and administration.*

FDA Label Image

Vial Option 2 (Vial Label Option 2)

FDA Label Image

Vial Option 3 (Vial Option 3)

This is a medication label for Propofol Injectable Emulsion used for intravenous administration on a single patient. The emulsion is made up of 1g of Propofol in 100mL of Soybean oil. The required dosage is specified on the packaging. It is recommended to use sterile techniques during administration as the emulsion is sterile and nonpyrogenic. The label contains the NDC number, expiry and storage instructions, as well as the composition of the emulsion. The medication must be discarded within 12 hours of opening. It is manufactured by Hospira Inc.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.